Mark McCamish is the founder of IconOVir Bio. IconOVir Bio has raised $77M in total funding. Latest round: Series A. Based in New York, NY, USA.
Mark McCamish is the President and CEO of IconOVir Bio, a preclinical-stage biotechnology company focused on oncolytic virus therapies. He previously served as President and CEO of Forty Seven, Inc., which was acquired by Gilead for $4.9 billion. He is recognized as an expert in biologic and biosimilars development.
Full founder directory · Investor directory · Company funding database · Fundraising library